JPS6047243B2 - immune booster - Google Patents
immune boosterInfo
- Publication number
- JPS6047243B2 JPS6047243B2 JP54021304A JP2130479A JPS6047243B2 JP S6047243 B2 JPS6047243 B2 JP S6047243B2 JP 54021304 A JP54021304 A JP 54021304A JP 2130479 A JP2130479 A JP 2130479A JP S6047243 B2 JPS6047243 B2 JP S6047243B2
- Authority
- JP
- Japan
- Prior art keywords
- conalbumin
- administered
- immune
- day
- immune booster
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108010026206 Conalbumin Proteins 0.000 claims description 11
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 229960001438 immunostimulant agent Drugs 0.000 description 3
- 239000003022 immunostimulating agent Substances 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000011597 hartley guinea pig Methods 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
【発明の詳細な説明】
本発明はコンアルブミンからなる免疫促進剤に関するも
のてある。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an immunostimulant comprising conalbumin.
免疫機構は、異種の抗原を識別し、処理排除するという
生体にそなわつた重要な機構であり、微生物などの病原
性物質の生体内への侵入、あるいは癌細胞などの生体内
で生じた異物に対し、防ぎよ桟橋として働く。The immune system is an important mechanism in living organisms that identifies and processes foreign antigens and eliminates them. Against this, it acts as a preventive pier.
免疫促進剤は、この免疫機能・を冗進するものてあり、
異物の抗原性が弱い場合、免疫桟能が低下している場合
などに特に用いられる。本発明は、コンアルブミンがこ
の免疫促進剤として有用であることを見出したものであ
る。Immune promoters enhance this immune function.
It is especially used when the antigenicity of the foreign substance is weak or when the immune system is weakened. The present invention has discovered that conalbumin is useful as this immunostimulant.
本発明のコンアルブミンとは、分子量約８７０００、等
電点６．０の糖蛋白質てあり、鶏卵の卵白蛋由中約１３
％をしめる。The conalbumin of the present invention is a glycoprotein with a molecular weight of about 87,000 and an isoelectric point of 6.0, and is derived from egg white protein of chicken eggs.
Close the percentage.
通常、卵白より分画して得られている。本発明のコンア
ルブミンは、経口投与により、体液性免疫および細胞性
免疫のいずれをも促進す表１、体液’住免疫、０次にそ
の薬理試験および急性毒性試験を示。It is usually obtained by fractionating egg white. The conalbumin of the present invention promotes both humoral immunity and cell-mediated immunity when administered orally.
）体液性免液
体重３５０〜４００ｙのハートレイ系モルモツト雌１０
匹にコンアルブミンを０．２％水溶液として５０ｍｌ／
日／匹 ８日間経口投与した。) 10 female Hartley Guinea pigs with humoral immunity liquid weight 350-400y
50 ml of conalbumin as a 0.2% aqueous solution was administered to each animal.
Day/mouse Oral administration for 8 days.
投与８日目に１ｍｇ／ｍｌ（７）ＨＢＳ抗原を２００μ
ｌフットパットに接種した。接種後１６日村に血清を採
取し、ＰＨＡ法〔「医学のあゆみ」第７８巻、第１２号
第７５９〜７６０頁（１９７１年）参照〕により抗体価
を測定した。なお、コンアルブミンを投与しなかつた群
（１０匹）を対照とした。結果を表１に示す。２） 細
胞性免疫
前記（１）のＨＢｓ抗原接種モルモツトについて、角膜
試験を行なつた。On the 8th day of administration, 200 μl of 1 mg/ml (7) HBS antigen was administered.
l footpads were inoculated. Serum was collected 16 days after inoculation, and the antibody titer was measured by the PHA method [see "Igaku no Ayumi" Vol. 78, No. 12, pp. 759-760 (1971)]. Note that a group (10 animals) to which conalbumin was not administered was used as a control. The results are shown in Table 1. 2) Cell-mediated immunity A corneal test was performed on the guinea pigs inoculated with the HBs antigen in (1) above.
接種後１４日目に、角膜に直径３〜＝の一過性の白濁が
生ずる量のＨＢｓ抗原（１１０ｍ９／ｍι）を再度接種
し、その４時間後の角膜の白濁の有無を判定した。結果
を表２に示す。（３１急性毒性
体重３５０〜４００ｑのハートレイ系モルモツト雌６匹
にコンアルブミン３０００ｍ９／Ｋ９／日を７日間経口
投与したが、死亡例はなく、また外観上なんらの異常は
認められなかつた。On the 14th day after inoculation, HBs antigen (110 m9/mι) was inoculated again in an amount that caused temporary white clouding with a diameter of 3 to 3 mm in the cornea, and the presence or absence of white clouding in the cornea was determined 4 hours later. The results are shown in Table 2. (31 Acute Toxicity) Conalbumin 3000 m9/K9/day was orally administered to 6 female Hartley guinea pigs weighing 350 to 400 q for 7 days, but there were no deaths and no abnormalities were observed in appearance.
以上に示したように、コンアルブミンは免疫促進剤とし
て有効であり、微生物により惑染症および癌の治療また
は予防、ワクチンの効力増強などの目的に使用しうる。As shown above, conalbumin is effective as an immunostimulant and can be used for purposes such as treatment or prevention of infectious diseases caused by microorganisms and cancer, and enhancement of vaccine efficacy.
コンアルブミンは成人１日当り１０〜５０００ｍ９経口
投与される。投与剤形としては、散剤、カプセル剤、顆
粒一剤、細粒剤、錠剤などがあげられ、これらは常法に
より製剤化できる。Conalbumin is administered orally at 10 to 5000 m9 per day for adults. Dosage forms include powders, capsules, single granules, fine granules, tablets, etc., and these can be formulated by conventional methods.
次に実施例を示す。Next, examples will be shown.
実施例１
錠剤
コンアルブミン５００ｙ１乳糖３００ｇ、コンスターチ
２１５ｙ１結晶セルロース１３０ｆを混合し、これによ
りポリビニルピロリドン４５ｙのエタノールを加えて練
合した後、円筒顆粒機で造粒した。Example 1 Tablets Conalbumin 500y1, lactose 300g, constarch 215y1, and crystalline cellulose 130f were mixed, and after kneading with the addition of polyvinylpyrrolidone 45y ethanol, the mixture was granulated using a cylindrical granulator.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP54021304A JPS6047243B2 (en) | 1979-02-27 | 1979-02-27 | immune booster |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP54021304A JPS6047243B2 (en) | 1979-02-27 | 1979-02-27 | immune booster |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS55113719A JPS55113719A (en) | 1980-09-02 |
| JPS6047243B2 true JPS6047243B2 (en) | 1985-10-21 |
Family
ID=12051398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP54021304A Expired JPS6047243B2 (en) | 1979-02-27 | 1979-02-27 | immune booster |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6047243B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0699313B2 (en) * | 1990-02-28 | 1994-12-07 | エーザイ株式会社 | Macrophage and neutrophil activator |
-
1979
- 1979-02-27 JP JP54021304A patent/JPS6047243B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS55113719A (en) | 1980-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3530526B2 (en) | Herpes simplex vaccine comprising HSV glycoprotein gD and 3 deacylated monophosphoryl lipid A | |
| JP2635444B2 (en) | Treatment of autoimmune diseases by oral administration of autoantibodies | |
| RU2390352C2 (en) | Adjuvant composition containing poly-gamma-glutamic acid | |
| HU227944B1 (en) | Vaccines containing a saponin and a sterol | |
| WO2015196935A1 (en) | Pharmaceutical composition containing cpg oligonucleotide | |
| MXPA03006819A (en) | Methods and compositions for treatment of immune dysfunction disorders. | |
| Carlsson et al. | Secretory and serum immunoglobulin class-specific antibodies to poliovirus after vaccination | |
| HU230545B1 (en) | Use of a composition of antigen and glycolipid adjuvant for sublingual administration | |
| Youssef et al. | Effect of subclinical lead toxicity on the immune response of chickens to Newcastle disease virus vaccine | |
| MXPA03006818A (en) | Methods and compositions for modulating the immune system of animals. | |
| CN113082202B (en) | Composite water-soluble animal vaccine adjuvant, vaccine and preparation method of vaccine | |
| Dahlman-Höglund et al. | Bystander suppression of the immune response to human serum albumin in rats fed ovalbumin | |
| JP2002534438A (en) | New treatment | |
| US4689224A (en) | Method for administering vaccines containing equine leukokines and compositions therefor | |
| Adler | In Vitro Studies on Allotype Suppression: I. Release from Allotype Suppression by Antibodies Specific for the Non-Suppressed Allotype | |
| JPS6047243B2 (en) | immune booster | |
| JPH09194393A (en) | Method for inducing immunological tolerance, immunological tolerance inducing food kit and immunological tolerance inducing agent kit | |
| US4039656A (en) | Production of attenuated viruses | |
| US4049794A (en) | Treatment of infections in animals | |
| JP3051444B2 (en) | Composition for preventing or treating autoimmune nephritis | |
| DE2616406A1 (en) | MEANS FOR PROPHYLAXIS AND THERAPY OF GASTRO-ENTERITIS | |
| JP2000053580A (en) | Use of peptide compound for treatment of systemic lupus erythematosus | |
| Olusi et al. | Effects of early protein-calorie malnutrition on the immune response | |
| Cunliffe et al. | Interferon inducers and foot-and-mouth disease vaccines: influence of two synthetic polynucleotides on antibody response and immunity in guinea pigs and swine | |
| AU2001236636B2 (en) | Human herpesvirus 6a and 6b transfer factors for the treatment of chronic fatigue syndrome and multiple sclerosis |